ICD Firms Urge Delay In MTWA Coverage Decision, Despite Doctors’ Support
This article was originally published in The Gray Sheet
Executive Summary
In a new argument, Medtronic contends that CMS' proposed national decision to cover Microvolt T-Wave Alternans testing may undermine the agency's efforts to cut costs
You may also be interested in...
St. Jude Stock Tumbles On T-Wave Alternans Coverage; Index Continues Slide
St. Jude Medical's stock ended the 2006 first quarter down 18% to $41 per share following CMS' decision to reimburse a device that can identify patients who are unlikely to benefit from an implantable cardioverter defibrillator, St. Jude's bread and butter
St. Jude Stock Tumbles On T-Wave Alternans Coverage; Index Continues Slide
St. Jude Medical's stock ended the 2006 first quarter down 18% to $41 per share following CMS' decision to reimburse a device that can identify patients who are unlikely to benefit from an implantable cardioverter defibrillator, St. Jude's bread and butter
CMS Proposes National Coverage For Microvolt T-Wave Alternan Testing
Cambridge Heart (HeartWave II) appears to have prevailed in its quest to obtain national coverage for Microvolt T-Wave Alternan testing to evaluate patients at risk of sudden cardiac death, despite opposition from professional societies and the three major ICD firms